AL001-3: A STUDY TO EVALUATE EFFICACY AND SAFETY OF AL001 IN FTD

ALECTOR

AL001

Alector, Inc. is studying AL001 as a new experimental drug for frontotemporal dementia (FTD) caused by mutations in the progranulin gene. These mutations reduce progranulin levels in the body and may lead to symptoms of FTD. The purpose of the phase 3 study is to learn whether increasing progranulin levels with treatment with AL001 will delay onset of symptoms or slow disease progression, when compared to a placebo (a solution that contains no active AL001 drug).



ELIGIBILITY

Each individual will be evaluated to determine eligibility. You may be eligible if:

You have a progranulin gene mutation and are at risk of developing FTD symptoms as evidenced by a biomarker

OR

You are diagnosed with FTD and have a progranulin gene mutation

MORE INFORMATION

AL001 or placebo will be administered every 4 weeks by an intravenous (IV) infusion. Assessments will include regular medical examinations, blood tests, brain imaging, and completion of questionnaires.

For all participants:

- You will be in the study about 2 years.
- You will need to visit the study site at least 1 time per month for 2 years.

Optional open-label extension (OLE):

- Participants who complete the study and who meet the criteria will be eligible to continue to the OLE.
- All participants will receive AL001.
- OLE duration is about 2 years.

AL001 has not been approved by the US Food and Drug Administration (FDA) or any other health authority around the world.

For more information about participating in this study, visit www.alectorftdtrial.com or please contact:

<Name> at <Institution Name>
<phone # / email address>

HELP SPARK NEW POSSIBILITIES IN FTD

ALECTOR

Version 3.0, 22 Feb 2021